{"id":57742,"date":"2026-02-24T18:07:17","date_gmt":"2026-02-24T10:07:17","guid":{"rendered":"https:\/\/flcube.com\/?p=57742"},"modified":"2026-02-24T18:07:18","modified_gmt":"2026-02-24T10:07:18","slug":"frontier-biotech-licenses-two-sirna-assets-to-gsk-in-1b-deal-expands-global-rnai-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57742","title":{"rendered":"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership"},"content":{"rendered":"\n<p><strong>Frontier Biotechnologies Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688221:SHA\">SHA:\u202f688221<\/a>)<\/strong> announced a <strong>licensing agreement<\/strong> with <strong>GlaxoSmithKline (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE:\u202fGSK<\/a>)<\/strong>, granting the UK pharmaceutical giant <strong>exclusive global rights<\/strong> to two <strong>small interfering RNA (siRNA)<\/strong> pipeline assets. The deal includes one candidate at the <strong>IND application stage<\/strong> and one <strong>preclinical candidate<\/strong>, positioning GSK to expand its RNA therapeutics portfolio through Frontier&#8217;s proprietary siRNA platform.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Frontier Biotechnologies Inc. (SHA:\u202f688221)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>GlaxoSmithKline (GSK, NYSE:\u202fGSK)<\/td><\/tr><tr><td><strong>Licensed Assets<\/strong><\/td><td>2 siRNA pipeline candidates<\/td><\/tr><tr><td><strong>Asset 1<\/strong><\/td><td>IND\u2011stage siRNA candidate<\/td><\/tr><tr><td><strong>Asset 2<\/strong><\/td><td>Preclinical siRNA candidate<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global exclusive rights<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>USD\u202f40\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to <strong>USD\u202f963\u202fmillion<\/strong> (across both programs)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on global net sales<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td><strong>&gt;\u202fUSD\u202f1\u202fbillion<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-responsibilities\">Development Responsibilities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Frontier Bio<\/th><th>GSK<\/th><\/tr><\/thead><tbody><tr><td><strong>Early\u2011Stage Development<\/strong><\/td><td>Lead Phase I in China (IND\u2011stage asset)<\/td><td>\u2013<\/td><\/tr><tr><td><strong>IND\u2011Enabling Studies<\/strong><\/td><td>Complete for preclinical asset<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Global Clinical Development (Phase II+)<\/strong><\/td><td>\u2013<\/td><td>Full responsibility<\/td><\/tr><tr><td><strong>Regulatory Filings<\/strong><\/td><td>\u2013<\/td><td>Global submissions<\/td><\/tr><tr><td><strong>Commercialization<\/strong><\/td><td>\u2013<\/td><td>Worldwide launch and sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-asset-profile-sirna-platform\">Strategic Asset Profile \u2013 siRNA Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology:<\/strong> <strong>Small interfering RNA (siRNA)<\/strong> \u2013 double\u2011stranded RNA molecules that silence specific genes through RNA interference<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Post\u2011transcriptional gene silencing by degrading target mRNA, preventing disease\u2011causing protein production<\/li>\n\n\n\n<li><strong>Pipeline Stage:<\/strong> One asset IND\u2011ready, one in preclinical development<\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> siRNA therapeutics offer <strong>durable, reversible gene silencing<\/strong> with potential applications across genetic diseases, cardiovascular, metabolic, and infectious disease indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Frontier&#8217;s Validation:<\/strong> The partnership with a <strong>Big Pharma leader<\/strong> validates Frontier&#8217;s <strong>siRNA discovery and early\u2011development capabilities<\/strong>, positioning the Chinese biotech as an emerging player in the global RNAi space.<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> The <strong>USD\u202f40\u202fmillion upfront<\/strong> provides non\u2011dilutive funding to advance early\u2011stage programs, while the <strong>USD\u202f963\u202fmillion milestone potential<\/strong> aligns Frontier&#8217;s interests with long\u2011term commercial success.<\/li>\n\n\n\n<li><strong>GSK&#8217;s RNAi Expansion:<\/strong> GSK gains access to <strong>novel siRNA candidates<\/strong> with differentiated targets, complementing its existing nucleic acid therapeutics portfolio and strengthening its position in the rapidly growing RNAi market.<\/li>\n\n\n\n<li><strong>Risk Sharing:<\/strong> The <strong>handoff structure<\/strong>\u2014Frontier manages early development, GSK takes global Phase II+\u2014optimizes resource allocation and leverages each partner&#8217;s core competencies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Biotech Global Licensing:<\/strong> The deal reinforces the <strong>accelerating trend<\/strong> of Chinese biotechs out\u2011licensing innovative platforms to multinational pharma, with Frontier joining peers like Alnylam partners and Ionis collaborators in the siRNA space.<\/li>\n\n\n\n<li><strong>RNAi Market Growth:<\/strong> The global siRNA therapeutics market is projected to exceed <strong>$10\u202fbillion<\/strong> by 2030, driven by approvals in cardiovascular, metabolic, and rare disease indications.<\/li>\n\n\n\n<li><strong>Valuation Benchmark:<\/strong> The <strong>>\u202f$1\u202fbillion total deal value<\/strong> sets a strong precedent for early\u2011stage Chinese RNAi assets, signaling continued Big Pharma appetite for novel gene\u2011silencing technologies.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievements, clinical development timelines, and commercial potential for the licensed siRNA assets. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, and competitive dynamics in the RNAi space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frontier Biotechnologies Inc. (SHA:\u202f688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE:\u202fGSK), granting the UK&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[320,278,184,914,64,1956],"class_list":["post-57742","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-frontier-biotechnologies","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-rnai-aso","tag-sha-688221"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Frontier Biotechnologies Inc. (SHA:\u202f688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE:\u202fGSK), granting the UK pharmaceutical giant exclusive global rights to two small interfering RNA (siRNA) pipeline assets. The deal includes one candidate at the IND application stage and one preclinical candidate, positioning GSK to expand its RNA therapeutics portfolio through Frontier&#039;s proprietary siRNA platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57742\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership\" \/>\n<meta property=\"og:description\" content=\"Frontier Biotechnologies Inc. (SHA:\u202f688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE:\u202fGSK), granting the UK pharmaceutical giant exclusive global rights to two small interfering RNA (siRNA) pipeline assets. The deal includes one candidate at the IND application stage and one preclinical candidate, positioning GSK to expand its RNA therapeutics portfolio through Frontier&#039;s proprietary siRNA platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57742\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T10:07:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T10:07:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57742#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57742\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership\",\"datePublished\":\"2026-02-24T10:07:17+00:00\",\"dateModified\":\"2026-02-24T10:07:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57742\"},\"wordCount\":489,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Frontier Biotechnologies\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"RNAi \\\/ ASO\",\"SHA: 688221\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57742#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57742\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57742\",\"name\":\"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-24T10:07:17+00:00\",\"dateModified\":\"2026-02-24T10:07:18+00:00\",\"description\":\"Frontier Biotechnologies Inc. (SHA:\u202f688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE:\u202fGSK), granting the UK pharmaceutical giant exclusive global rights to two small interfering RNA (siRNA) pipeline assets. The deal includes one candidate at the IND application stage and one preclinical candidate, positioning GSK to expand its RNA therapeutics portfolio through Frontier's proprietary siRNA platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57742#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57742\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57742#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Frontier Biotechnologies Inc. (SHA:\u202f688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE:\u202fGSK), granting the UK pharmaceutical giant exclusive global rights to two small interfering RNA (siRNA) pipeline assets. The deal includes one candidate at the IND application stage and one preclinical candidate, positioning GSK to expand its RNA therapeutics portfolio through Frontier's proprietary siRNA platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57742","og_locale":"en_US","og_type":"article","og_title":"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership","og_description":"Frontier Biotechnologies Inc. (SHA:\u202f688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE:\u202fGSK), granting the UK pharmaceutical giant exclusive global rights to two small interfering RNA (siRNA) pipeline assets. The deal includes one candidate at the IND application stage and one preclinical candidate, positioning GSK to expand its RNA therapeutics portfolio through Frontier's proprietary siRNA platform.","og_url":"https:\/\/flcube.com\/?p=57742","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-24T10:07:17+00:00","article_modified_time":"2026-02-24T10:07:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57742#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57742"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership","datePublished":"2026-02-24T10:07:17+00:00","dateModified":"2026-02-24T10:07:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57742"},"wordCount":489,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Frontier Biotechnologies","GlaxoSmithKline","GSK","NYSE: GSK","RNAi \/ ASO","SHA: 688221"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57742#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57742","url":"https:\/\/flcube.com\/?p=57742","name":"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-24T10:07:17+00:00","dateModified":"2026-02-24T10:07:18+00:00","description":"Frontier Biotechnologies Inc. (SHA:\u202f688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE:\u202fGSK), granting the UK pharmaceutical giant exclusive global rights to two small interfering RNA (siRNA) pipeline assets. The deal includes one candidate at the IND application stage and one preclinical candidate, positioning GSK to expand its RNA therapeutics portfolio through Frontier's proprietary siRNA platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57742#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57742"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57742#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal \u2013 Expands Global RNAi Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57742"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57742\/revisions"}],"predecessor-version":[{"id":57744,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57742\/revisions\/57744"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}